Tinea Pharmaceuticals Report issue

Contributed to NME For profit Phase 3
Founded: Palo Alto CA United States (2004)
Status: Defunct (2017)

Organization Overview

First Clinical Trial
2009
NCT00869336
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2012

Timeline

NOW
  • Now

Alternative names

Topica Pharmaceuticals

Active Ingredients

Drugs in Phase 3 Trials (1)

luliconazole (luzu) (4 trials)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Onychomycosis (Phase 3)

Tinea (Phase 3)

Tinea Pedis (Phase 3)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 4
  • # of Trial APIs: 1